Healthcare’s Digital Transformation Is Accelerating — Here’s What That Means for Investors May 06, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The healthcare industry is undergoing a major digital shift, with leaders betting heavily on AI, automation, and advanced analytics to cut costs and improve backend systems like billing. A recent Everest Group survey, backed by Omega Healthcare, found that 85% of healthcare execs expect AI to drive greater efficiency in the near future. From AI “employees” managing multiple tasks to scent-detecting sensors and emerging tools in mental health, artificial intelligence is moving from buzzword to backbone in healthcare operations. As this transformation gains momentum, several companies are stepping up with fresh innovations—among them Avant Technologies, Inc. (OTCQB: AVAI), Alphabet Inc. (NASDAQ: GOOG, GOOGL), Royal Philips (Philips) (NYSE: PHG), Novo Nordisk A/S (NYSE: NVO), and NVIDIA Corporation (NASDAQ: NVDA). A recent PYMNTS Intelligence poll of C-suite leaders at billion-dollar healthcare firms found that 90% are already seeing a return on their generative AI investments. Looking ahead, analysts estimate that by 2035, AI could contribute an additional $461 billion in value to a healthcare sector already projected to hit $2.26 trillion. Avant Technologies, Inc. (OTCQB: AVAI), an emerging leader in AI-driven healthcare innovation, continues to accelerate its push into AI-powered healthcare diagnostics through its joint venture with Ainnova Tech, operating through Ai-nova Acquisition Corp. (AAC), a jointly controlled entity that holds global licensing rights to VisionAI and its supporting hardware. The two companies recently announced that the FDA has officially received their request for a pre-submission meeting for VisionAI, the joint venture’s flagship screening platform. This marked a pivotal moment in Avant’s trajectory. VisionAI uses a combination of retinal imaging, patient vitals, and advanced algorithms to identify early warning signs of diabetic retinopathy, cardiovascular disease, liver fibrosis, kidney disease, and type 2 diabetes—often before symptoms are visible. Studies show that AI tools can detect diabetic retinopathy and other chronic conditions with sensitivities exceeding 90%, often identifying issues before symptoms appear—according to NIH. "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where VisionAI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,” said Vinicio Vargas, CEO at Ainnova and a member of AAC's Board of Directors. “Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product." The upcoming FDA meeting will help finalize the clinical trial design and confirm the regulatory pathway for a 510(k) submission in the U.S., setting the stage for broader deployment. What sets AVAI apart from many AI-in-healthcare names is that its technology is already in the field. VisionAI has been rolled out through commercial pilot programs across Latin America, including Chile, the Dominican Republic, Mexico, and Brazil. These early deployments are generating real-world data while demonstrating how early diagnostics can reduce system-wide costs and improve outcomes in primary care environments. In recent months, AAC expanded its portfolio with four newly licensed diagnostic algorithms from one of Asia’s largest healthcare networks, validated on more than 2.3 million clinical cases. These models are now integrated into VisionAI to enhance its detection capabilities across multiple chronic disease categories. On the clinical development front, Avant’s partner Ainnova has brought on global contract research organization Fortrea to help guide its FDA strategy. With both emerging-market traction and U.S. regulatory progress advancing in parallel, the company appears to be executing on a dual-pronged strategy: building early market access where regulatory barriers are lower, while preparing for the commercial scale and reimbursement potential of the U.S. healthcare system. For investors tracking small-cap companies operating at the intersection of AI, diagnostics, and chronic disease management, Avant Technologies may be worth a closer look. As the FDA process moves forward and pilot programs scale, AVAI sits in a rare position—commercially active, globally licensed, and now formally in dialogue with U.S. regulators. CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ Alphabet Inc. (NASDAQ: GOOG, GOOGL), through its Google Cloud division, recently launched its Agent Garden and Agent2Agent Protocol, tools designed to deploy and coordinate intelligent AI agents. These agents can automate multi-step administrative and clinical workflows, extending beyond traditional chatbot capabilities. The system now allows independently built agents to collaborate, creating opportunities to optimize operations like billing, scheduling, and care navigation. Early users include Highmark Health and Hackensack Meridian, who are integrating these tools to reduce friction in patient and provider experiences. Royal Philips (Philips) (NYSE: PHG) recently expanded its partnership with Ibex Medical Analytics, further advancing AI adoption in digital pathology with the release of PIPS 6.0, a more integrated, efficient platform for cancer diagnosis. The system combines Philips’ pathology imaging with Ibex’s AI tools for breast, prostate, and gastric cancers, improving accuracy and boosting lab productivity. “Pathology provides key information for a precise diagnosis,” said Sam Terese, President & CEO of Alverno Laboratories. “The Philips and Ibex solutions are especially beneficial to the diagnosis of cancer cases because they aid our pathologists in making an accurate and quick diagnosis. These integrated pathology solutions help us provide the highest possible quality result that any lab can deliver, getting answers back to our clinicians quickly and saving patients sleepless nights, even on complex cases.” New features include enhanced workflows, automated case prioritization, and direct cloud archiving via Amazon Web Services. As demand for pathology services rises, this collaboration aims to relieve strain on pathologists while improving patient care. Novo Nordisk A/S (NYSE: NVO), through its Novo Nordisk Foundation is offering up to DKK 50 million (roughly US$7.58 million) in GPU hour grants to support academic research projects utilizing Denmark’s advanced Gefion AI supercomputer. “Our aim is to make it possible to accelerate research using powerful AI technology,” said Lene Oddershede, Senior Vice President for Natural & Technical Sciences at the Novo Nordisk Foundation. “With these grants, we wish to bridge the gap until the research community has included compute costs on their funding budgets. The grants also serve a second purpose, which is to fully utilise the available capacity of Gefion and make it possible for the research community to harvest the value provided by Gefion.” The initiative is intended to help researchers overcome cost barriers during the transition to fully budgeted compute access. Eligible projects must align with health, sustainability, or life sciences and be capable of scaling AI workloads across multiple GPUs. With Gefion now operating commercially, the Foundation aims to maximize its scientific utility while accelerating breakthroughs in core focus areas. At the International Conference on Learning Representations (ICLR) 2025 conference held in April, NVIDIA Corporation (NASDAQ: NVDA) showcased over 70 research papers, many with direct relevance to healthcare innovation. “ICLR is one of the world’s most impactful AI conferences, where researchers introduce important technical innovations that move every industry forward,” said Bryan Catanzaro, vice president of applied deep learning research at NVIDIA. “The research we’re contributing this year aims to accelerate every level of the computing stack to amplify the impact and utility of AI across industries.” Among the highlights was Proteina, a transformer-based model capable of generating diverse, designable protein backbones — a potential breakthrough for drug discovery and biomedical research. These advances reinforce NVIDIA’s full-stack AI strategy, now driving real-world applications across diagnostics, precision medicine, and bioinformatics. Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT: Baystreet.ca [email protected] (250) 661-3391 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Healthcare’s Digital Transformation Is Accelerating — Here’s What That Means for Investors May 06, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The healthcare industry is undergoing a major digital shift, with leaders betting heavily on AI, automation, and advanced analytics to cut costs and improve backend systems like billing. A recent Everest Group survey, backed by Omega Healthcare, found that 85% of healthcare execs expect AI to drive greater efficiency in the near future. From AI “employees” managing multiple tasks to scent-detecting sensors and emerging tools in mental health, artificial intelligence is moving from buzzword to backbone in healthcare operations. As this transformation gains momentum, several companies are stepping up with fresh innovations—among them Avant Technologies, Inc. (OTCQB: AVAI), Alphabet Inc. (NASDAQ: GOOG, GOOGL), Royal Philips (Philips) (NYSE: PHG), Novo Nordisk A/S (NYSE: NVO), and NVIDIA Corporation (NASDAQ: NVDA). A recent PYMNTS Intelligence poll of C-suite leaders at billion-dollar healthcare firms found that 90% are already seeing a return on their generative AI investments. Looking ahead, analysts estimate that by 2035, AI could contribute an additional $461 billion in value to a healthcare sector already projected to hit $2.26 trillion. Avant Technologies, Inc. (OTCQB: AVAI), an emerging leader in AI-driven healthcare innovation, continues to accelerate its push into AI-powered healthcare diagnostics through its joint venture with Ainnova Tech, operating through Ai-nova Acquisition Corp. (AAC), a jointly controlled entity that holds global licensing rights to VisionAI and its supporting hardware. The two companies recently announced that the FDA has officially received their request for a pre-submission meeting for VisionAI, the joint venture’s flagship screening platform. This marked a pivotal moment in Avant’s trajectory. VisionAI uses a combination of retinal imaging, patient vitals, and advanced algorithms to identify early warning signs of diabetic retinopathy, cardiovascular disease, liver fibrosis, kidney disease, and type 2 diabetes—often before symptoms are visible. Studies show that AI tools can detect diabetic retinopathy and other chronic conditions with sensitivities exceeding 90%, often identifying issues before symptoms appear—according to NIH. "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where VisionAI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,” said Vinicio Vargas, CEO at Ainnova and a member of AAC's Board of Directors. “Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product." The upcoming FDA meeting will help finalize the clinical trial design and confirm the regulatory pathway for a 510(k) submission in the U.S., setting the stage for broader deployment. What sets AVAI apart from many AI-in-healthcare names is that its technology is already in the field. VisionAI has been rolled out through commercial pilot programs across Latin America, including Chile, the Dominican Republic, Mexico, and Brazil. These early deployments are generating real-world data while demonstrating how early diagnostics can reduce system-wide costs and improve outcomes in primary care environments. In recent months, AAC expanded its portfolio with four newly licensed diagnostic algorithms from one of Asia’s largest healthcare networks, validated on more than 2.3 million clinical cases. These models are now integrated into VisionAI to enhance its detection capabilities across multiple chronic disease categories. On the clinical development front, Avant’s partner Ainnova has brought on global contract research organization Fortrea to help guide its FDA strategy. With both emerging-market traction and U.S. regulatory progress advancing in parallel, the company appears to be executing on a dual-pronged strategy: building early market access where regulatory barriers are lower, while preparing for the commercial scale and reimbursement potential of the U.S. healthcare system. For investors tracking small-cap companies operating at the intersection of AI, diagnostics, and chronic disease management, Avant Technologies may be worth a closer look. As the FDA process moves forward and pilot programs scale, AVAI sits in a rare position—commercially active, globally licensed, and now formally in dialogue with U.S. regulators. CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ Alphabet Inc. (NASDAQ: GOOG, GOOGL), through its Google Cloud division, recently launched its Agent Garden and Agent2Agent Protocol, tools designed to deploy and coordinate intelligent AI agents. These agents can automate multi-step administrative and clinical workflows, extending beyond traditional chatbot capabilities. The system now allows independently built agents to collaborate, creating opportunities to optimize operations like billing, scheduling, and care navigation. Early users include Highmark Health and Hackensack Meridian, who are integrating these tools to reduce friction in patient and provider experiences. Royal Philips (Philips) (NYSE: PHG) recently expanded its partnership with Ibex Medical Analytics, further advancing AI adoption in digital pathology with the release of PIPS 6.0, a more integrated, efficient platform for cancer diagnosis. The system combines Philips’ pathology imaging with Ibex’s AI tools for breast, prostate, and gastric cancers, improving accuracy and boosting lab productivity. “Pathology provides key information for a precise diagnosis,” said Sam Terese, President & CEO of Alverno Laboratories. “The Philips and Ibex solutions are especially beneficial to the diagnosis of cancer cases because they aid our pathologists in making an accurate and quick diagnosis. These integrated pathology solutions help us provide the highest possible quality result that any lab can deliver, getting answers back to our clinicians quickly and saving patients sleepless nights, even on complex cases.” New features include enhanced workflows, automated case prioritization, and direct cloud archiving via Amazon Web Services. As demand for pathology services rises, this collaboration aims to relieve strain on pathologists while improving patient care. Novo Nordisk A/S (NYSE: NVO), through its Novo Nordisk Foundation is offering up to DKK 50 million (roughly US$7.58 million) in GPU hour grants to support academic research projects utilizing Denmark’s advanced Gefion AI supercomputer. “Our aim is to make it possible to accelerate research using powerful AI technology,” said Lene Oddershede, Senior Vice President for Natural & Technical Sciences at the Novo Nordisk Foundation. “With these grants, we wish to bridge the gap until the research community has included compute costs on their funding budgets. The grants also serve a second purpose, which is to fully utilise the available capacity of Gefion and make it possible for the research community to harvest the value provided by Gefion.” The initiative is intended to help researchers overcome cost barriers during the transition to fully budgeted compute access. Eligible projects must align with health, sustainability, or life sciences and be capable of scaling AI workloads across multiple GPUs. With Gefion now operating commercially, the Foundation aims to maximize its scientific utility while accelerating breakthroughs in core focus areas. At the International Conference on Learning Representations (ICLR) 2025 conference held in April, NVIDIA Corporation (NASDAQ: NVDA) showcased over 70 research papers, many with direct relevance to healthcare innovation. “ICLR is one of the world’s most impactful AI conferences, where researchers introduce important technical innovations that move every industry forward,” said Bryan Catanzaro, vice president of applied deep learning research at NVIDIA. “The research we’re contributing this year aims to accelerate every level of the computing stack to amplify the impact and utility of AI across industries.” Among the highlights was Proteina, a transformer-based model capable of generating diverse, designable protein backbones — a potential breakthrough for drug discovery and biomedical research. These advances reinforce NVIDIA’s full-stack AI strategy, now driving real-world applications across diagnostics, precision medicine, and bioinformatics. Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT: Baystreet.ca [email protected] (250) 661-3391 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.